Castle Biosciences Revenue 2011-2026 | CSTL

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Castle Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
332 M	220 M	137 M	94.1 M	62.6 M	51.9 M	22.8 M	13.8 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
332 M	13.8 M	117 M

Quarterly Revenue Castle Biosciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
83 M	86.2 M	88 M	-	85.8 M	87 M	73 M	-	61.5 M	50.1 M	42 M	-	37 M	34.8 M	26.9 M	-	23.5 M	22.8 M	22.8 M	17.3 M	15.2 M	12.7 M	17.4 M	17.6 M	14.8 M	10.7 M	8.72 M	11.4 M	3.71 M	3.98 M	3.66 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
88 M	3.66 M	35.6 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Diagnostics research industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	128 M	-	-6.23 %	$ 30.6 M	Germany
Agilent Technologies A	6.32 B	$ 116.96	1.23 %	$ 35.6 B	USA
Akumin AKU	750 M	-	-17.87 %	$ 25.9 M	Canada
Accelerate Diagnostics AXDX	2.97 M	-	-61.36 %	$ 2.46 M	USA
Co-Diagnostics CODX	622 K	$ 1.72	2.99 %	$ 2.29 M	USA
Aspira Women's Health AWH	343 K	-	-6.19 %	$ 10.5 M	USA
Biocept BIOC	25.9 M	-	-13.05 %	$ 7.29 M	USA
Chembio Diagnostics CEMI	49.5 M	-	0.22 %	$ 16.8 M	USA
CareDx, Inc CDNA	380 M	$ 21.37	0.66 %	$ 1.14 B	USA
Oxford Immunotec Global PLC OXFD	73.7 M	-	-	$ 562 M	Britain
DermTech DMTK	15.3 M	-	-11.32 %	$ 2.94 M	USA
Enzo Biochem ENZ	31.9 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	3.25 B	-	-	$ 19.8 B	USA
Fulgent Genetics FLGT	283 M	$ 16.33	0.12 %	$ 494 M	USA
Illumina ILMN	4.37 B	$ 128.0	0.09 %	$ 20.4 B	USA
Global Cord Blood Corporation CO	1.24 B	-	-	$ 399 M	China
Fluidigm Corporation FLDM	138 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	6.79 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	651 M	-	0.12 %	$ 80.1 M	China
Charles River Laboratories International CRL	4.02 B	$ 171.98	1.3 %	$ 8.52 B	USA
PRA Health Sciences, Inc. PRAH	3.18 B	-	-	$ 10.7 B	USA
Guardant Health GH	982 M	$ 88.84	-0.08 %	$ 11.1 B	USA
Lantheus Holdings LNTH	1.54 B	$ 84.31	-0.03 %	$ 5.69 B	USA
HTG Molecular Diagnostics HTGM	6.37 M	-	-20.0 %	$ 1.06 M	USA
Heska Corporation HSKA	257 M	-	-	$ 1.31 B	USA
Interpace Biosciences IDXG	38.7 M	$ 1.98	-2.37 %	$ 8.76 M	USA
Medpace Holdings MEDP	2.53 B	$ 412.77	0.54 %	$ 11.9 B	USA
Koninklijke Philips N.V. PHG	17.8 B	$ 27.63	0.58 %	$ 20 B	Niderland
Motus GI Holdings MOTS	319 K	-	-34.28 %	$ 263 K	Israel
QIAGEN N.V. QGEN	2.25 B	-	-	$ 10.6 B	Niderland
Senseonics Holdings SENS	35.3 M	$ 7.05	-	$ 294 M	USA
Neogen Corporation NEOG	895 M	$ 9.6	0.58 %	$ 2.08 B	USA
Biomerica BMRA	5.31 M	$ 2.12	-0.93 %	$ 4.87 M	USA
National Research Corporation NRC	137 M	$ 17.33	0.55 %	$ 388 M	USA
ICON Public Limited Company ICLR	5.48 B	$ 101.21	-0.94 %	$ 8.35 B	Irlanda
Laboratory Corporation of America Holdings LH	14 B	$ 263.81	0.03 %	$ 21.9 B	USA
Thermo Fisher Scientific TMO	44.6 B	$ 473.8	0.9 %	$ 179 B	USA
Trinity Biotech plc TRIB	61.6 M	$ 0.64	-1.34 %	$ 61.9 M	Irlanda
OpGen OPGN	5.2 M	-	-16.95 %	$ 1.54 M	USA
NeoGenomics NEO	727 M	$ 8.41	1.45 %	$ 1.08 B	USA
Twist Bioscience Corporation TWST	377 M	$ 61.16	0.36 %	$ 3.66 B	USA
Myriad Genetics MYGN	824 M	$ 4.91	2.72 %	$ 455 M	USA
Natera NTRA	820 M	$ 206.02	1.11 %	$ 20.3 B	USA
Quest Diagnostics Incorporated DGX	11 B	$ 196.49	0.14 %	$ 21.8 B	USA
Invitae Corporation NVTA	122 M	-	-	$ 21.2 M	USA
PerkinElmer PKI	2.86 B	-	-0.91 %	$ 14.7 B	USA
Organovo Holdings ONVO	144 K	-	-2.3 %	$ 19.4 M	USA